Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease

Don D. Sin1,2*, Bruce E. Miller*, Annelyse Duvoix*, S. F. Paul Man1,2, Xuekui Zhang1, Edwin K. Silverman5, John E. Connett6, Nicholas A. Anthonisen7, Robert A. Wise8, Donald Tashkin9, Bartolome R. Celli10, Lisa D. Edwards11, Nicholas Locantore11, William MacNee12, Ruth Tal-Singer3, and David A. Lomas4; on behalf of the ECLIPSE Investigators

1UBC James Hogg Research Centre and Providence Heart and Lung Institute at St. Paul's Hospital, and 2Pulmonary Division, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; 3COPD Clinical Discovery, Respiratory Center of Excellence for Drug Discovery, GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania; 4Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; 5Channing Laboratory and Pulmonary and Critical Care Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; 6University of Minnesota School of Public Health, Minneapolis, Minnesota; 7Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; 8Johns Hopkins University School of Medicine, Baltimore, Maryland; 9University of California at Los Angeles School of Medicine, Los Angeles, California; 10Pulmonary and Critical Care Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; 11Biomedical Data Sciences, Respiratory Medicines Development Center, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina; and 12MRC Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom

Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum.

Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality.

Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study.

Measurements and Main Results: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort.

Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.

Clinical trial registered with www.clinicaltrials.gov (NCT 00292552).

Keywords: biomarker; chronic obstructive pulmonary disease; PARC/CCL-18; chemokine

Chronic obstructive pulmonary disease (COPD) is a major health burden worldwide, affecting 10 to 15% of the adult population 40 years and older (1) and responsible for 3 million deaths annually (2). Although there has been rapid expansion in our understanding of COPD pathogenesis, therapeutic options remain limited. One major barrier to drug discovery has been the lack of reliable, robust, reproducible, and modifiable biomarkers that can act as intermediate surrogate endpoints for clinical studies (3). Although biomarkers can be obtained from any organ, the most attractive is blood because it is readily accessible and its measurements can be easily standardized. However, because most serum proteins are secreted by non-pulmonary organs such as the liver and the bone marrow, their use may be limited in COPD. This problem is largely avoided for proteins secreted predominantly by the lungs (i.e., pneumoproteins). PARC (pulmonary and activation-regulated chemokine)/CCL-18 (CC-chemokine ligand-18) is a 7-kD protein that is constitutively expressed by monocytes/macrophages and dendritic cells and is secreted predominantly in the lungs (4). Although the exact biological role of PARC/CCL-18 is not known, serum levels are elevated in acute coronary syndromes (5), with idiopathic pulmonary fibrosis (6), and in childhood acute lymphoblastic leukemia (7). Interestingly, in idiopathic pulmonary fibrosis, serum PARC/CCL-18 levels may reflect fibrotic activity and correlate with survival (8). Pertinent to COPD, in one small study of patients with mild to moderate disease, serum PARC/CCL-18 levels were significantly associated with reduced FEV1 and with the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) Index score (9), whereas in another, circulating PARC/CCL-18 levels were found to associate with acute exacerbations (10). Although these data are promising, several critical questions remain.

(Received in original form August 5, 2010; accepted in final form January 7, 2011)

Supported jointly by the Canadian Institutes of Health Research (CIHR) and GlaxoSmithKline through a CIHR BXD program. The Lung Health Study was sponsored by contract N01-HR-46002 from the Division of Lung Diseases of the National Heart, Lung, and Blood Institute. ECLIPSE (SCO104960) was funded by GlaxoSmithKline.

* These authors made equal contributions to this work.

‡ Joint senior authors.

Correspondence and requests for reprints should be addressed to D. Sin, M.D., UBC James Hogg Research Centre, St. Paul’s Hospital, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6 Canada. E-mail: don.sin@hli.ubc.ca

This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org


Originally Published in Press as DOI: 10.1164/rcrm.201008-1220OC on January 14, 2011

Internet address: www.atsjournals.org
unanswered regarding the possible use of PARC/CCL-18 as a biomarker in COPD, including its relationship with clinical outcomes such as hospitalization and mortality and its responsiveness to pharmacologic therapy. Using two large COPD cohorts, we determined the relationship of serum PARC/CCL-18 levels with lung function and mortality and determined whether PARC/CCL-18 levels can be down-regulated by prednisolone as a proof-of-concept that they can be modulated by an antiinflammatory drug. Some of the data have been published previously in abstract form (11).

**METHODS**

See the online supplement for the details on methods.

**Subjects and Cohorts**

For this study, we used data from three COPD cohorts: (1) the Lung Health Study (LHS, NCT00000568), (2) Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE), and (3) a prednisolone intervention study. The details of these cohorts have been previously published (12–14) and can be found in the online supplement. LHS enrolled smokers between the ages of 35 to 60 years who had mild to moderate airflow obstruction as defined by an FEV1 of less than 90% but at least 55% of predicted, in the presence of an FEV1/FVC ratio less than 0.70. At the fifth annual visit, venipuncture was performed on 4,825 LHS participants, representing 89% of subjects known to be alive at Year 5. During the follow-up, the participants’ vital status was captured semiannually. Vital status was successfully determined for 98.3% of the participants (15). On the basis of adjudication by an expert panel, mortality end points in LHS were classified as follows: malignancies; respiratory failure; coronary heart disease (CHD); and cardiovascular disease (CVD), which included CHD as well as other CVDs such as stroke (15).

**ECLIPSE**

ECLIPSE (NCT00292552, GlaxoSmithKline study no. SCO104960) is a 3-year multicenter longitudinal observational study to identify novel end points in COPD. Individuals aged 40–75 years were recruited to the study if they had a smoking history of at least 10 pack-years; a postbronchodilator FEV1/FVC ratio not exceeding 0.7; and GOLD (Global Initiative for Obstructive Lung Disease) stage II (FEV1, 50–80% predicted), III (30% < FEV1, <50% predicted), or IV (FEV1 < 30% predicted) COPD (16). Smoking (>10 pack-years) and nonsmoking (<1 pack-year) control subjects were enrolled if they had normal lung function (postbronchodilator FEV1 > 85% predicted and FEV1/FVC > 0.7).

**RESULTS**

**Serum PARC/CCL-18 in LHS**

The baseline characteristics of subjects at the time of blood collection for both LHS and ECLIPSE are summarized in Table 1. In the LHS, there were 329 deaths (6.8%) of the LHS subjects in whom PARC/CCL-18 levels were determined. Of the LHS

<table>
<thead>
<tr>
<th>TABLE 1. BASELINE CHARACTERISTICS OF LHS AND ECLIPSE COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung Health Study</strong></td>
</tr>
<tr>
<td>-----------------------</td>
</tr>
<tr>
<td>Number of subjects</td>
</tr>
<tr>
<td><strong>Age, yr</strong></td>
</tr>
<tr>
<td>Men</td>
</tr>
<tr>
<td>White</td>
</tr>
<tr>
<td>Pack-years of smoking</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
</tr>
<tr>
<td>FEV₁, L</td>
</tr>
<tr>
<td>FEV₁, % predicted</td>
</tr>
<tr>
<td>Intermittent smokers</td>
</tr>
<tr>
<td>Continuing smokers</td>
</tr>
<tr>
<td>Chronic sputum*</td>
</tr>
<tr>
<td>Chronic cough*</td>
</tr>
<tr>
<td>PARC/CCL-18, ng/ml³</td>
</tr>
</tbody>
</table>

**Definition of abbreviations:** BMI = body mass index; COPD = chronic obstructive pulmonary disease; ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; LHS = Lung Health Study; N/A = not available; PARC/CCL-18 = pulmonary and activation-regulated chemokine/CC-chemokine ligand-18.

Continuous data are expressed as means (SD) and dichotomous variables are expressed as number (percentage of column totals). Serum PARC/CCL-18 concentrations are expressed as medians (median absolute deviation).

* At baseline.

³ Median (median absolute deviation).
TABLE 2. RELATIONSHIP BETWEEN SERUM PARC/CCL-18 CONCENTRATIONS AND TOTAL MORTALITY, CORONARY HEART DISEASE, AND CARDIOVASCULAR HOSPITALIZATION AND MORTALITY IN THE LUNG HEALTH STUDY

<table>
<thead>
<tr>
<th>End Point</th>
<th>PARC/CCL-18 as Continuous Variable (log scale)</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Q5 (highest)</th>
<th>P Value for Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total mortality</td>
<td>1.14 (0.93, 1.38)</td>
<td>1.16 (0.80, 1.70)</td>
<td>1.15 (0.80, 1.67)</td>
<td>1.24 (0.86, 1.79)</td>
<td>1.25 (0.87, 1.80)</td>
<td>0.27</td>
</tr>
<tr>
<td>Coronary heart disease deaths</td>
<td>1.26 (0.76, 2.08)</td>
<td>1.04 (0.32, 3.42)</td>
<td>2.44 (0.89, 6.72)</td>
<td>1.48 (0.50, 4.38)</td>
<td>1.52 (0.52, 4.43)</td>
<td>0.45</td>
</tr>
<tr>
<td>Cardiovascular deaths</td>
<td>1.20 (0.82, 1.77)</td>
<td>0.77 (0.34, 1.74)</td>
<td>1.10 (0.53, 2.30)</td>
<td>1.18 (0.57, 2.44)</td>
<td>1.05 (0.51, 2.17)</td>
<td>0.54</td>
</tr>
<tr>
<td>CHD hospitalization and deaths</td>
<td>1.33 (1.14, 1.56)</td>
<td>1.28 (0.90, 1.82)</td>
<td>1.63 (1.17, 2.26)</td>
<td>1.74 (1.25, 2.41)</td>
<td>1.83 (1.33, 2.53)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CVD hospitalization and deaths</td>
<td>1.28 (1.13, 1.45)</td>
<td>1.15 (0.89, 1.49)</td>
<td>1.22 (0.95, 1.56)</td>
<td>1.53 (1.20, 1.94)</td>
<td>1.51 (1.19, 1.91)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Definition of abbreviations: CHD = coronary heart disease; CVD = cardiovascular disease (which includes CHD); PARC/CCL-18 = pulmonary and activation-regulated chemokine/CC-chemokine ligand-18; Q = quintile.

Each cell expresses an adjusted hazards ratio (95% confidence interval) using quintile 1 as the referent, adjusted for covariates selected by LASSO (least absolute shrinkage and selection operator) from age, sex, FEV₁ (percentage of predicted normal values), current smoking status, pack-years of smoking, body mass index, and other covariates (see Methods).

TABLE 3. CLINICAL VARIABLES ASSOCIATED WITH SERUM PARC/CCL-18 CONCENTRATIONS IN LHS AND ECLIPSE PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

<table>
<thead>
<tr>
<th>Change in Variable</th>
<th>LHS (Relative Ratio (95% CI))</th>
<th>P Value</th>
<th>ECLIPSE COPD (Relative Ratio (95% CI))</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-yr increase in age</td>
<td>1.09 (1.06, 1.12)</td>
<td>&lt;0.001</td>
<td>1.09 (1.07, 1.12)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Males vs. females</td>
<td>1.10 (1.06, 1.14)</td>
<td>&lt;0.001</td>
<td>1.05 (1.02, 1.09)</td>
<td>0.004</td>
</tr>
<tr>
<td>10-pack-year smoking increase</td>
<td>1.01 (1.00, 1.02)</td>
<td>0.068</td>
<td>1.00 (0.99, 1.01)</td>
<td>0.984</td>
</tr>
<tr>
<td>One unit change in BMI, kg/m²</td>
<td>1.02 (1.01, 1.02)</td>
<td>&lt;0.001</td>
<td>1.01 (1.00, 1.02)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV₁ increase of 10% predicted</td>
<td>0.97 (0.96, 0.98)</td>
<td>&lt;0.001</td>
<td>1.00 (0.99, 1.01)</td>
<td>0.737</td>
</tr>
<tr>
<td>Continuing smokers vs. quitters*</td>
<td>0.95 (0.90, 0.99)</td>
<td>0.016</td>
<td>0.93 (0.90, 0.96)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Definition of abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease; ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; LHS = Lung Health Study; PARC/CCL-18 = pulmonary and activation-regulated chemokine/CC-chemokine ligand-18.

* Change in individual variables holding other covariates fixed at their mean value.

* For ECLIPSE, this compares current smokers versus former smokers.
to 98 ng/ml at 2 weeks ($P < 0.001$ vs. placebo; see Figure E3). See the online supplement for additional results.

**DISCUSSION**

Using two large COPD cohorts and an intervention study, PARC/CCL-18 appears to be a promising blood biomarker in COPD by fulfilling some of the important criteria of a biomarker, including its independent association with lung function, morbidity and mortality, and responsiveness to therapy (18). First, in the ECLIPSE study, we found that serum PARC/CCL-18 concentrations were independently related to COPD; whereas in the LHS, a large cohort of smokers with mild to moderate COPD (GOLD stages I and II), we found a significant relationship with lung function, as measured by FEV$_1$ percent predicted. Second, we observed a strong, independent relationship of PARC/CCL-18 concentrations with future risk of cardiovascular hospitalization and mortality (in the LHS) and with total mortality (in ECLIPSE). Third, in the prednisolone interventional study, we found that serum PARC/CCL-18 levels could be modified by the short-term use of prednisolone, similar to what has been previously reported (19), which suggests that PARC/CCL-18 may be modifiable by systemic antiinflammatory therapy. Together, these data suggest that PARC/CCL-18 may be a useful candidate blood biomarker in COPD.

PARC/CCL-18 is an $\sim$7-kD protein, which is expressed mainly by dendritic cells (20) and alternatively activated (M2) macrophages in the lungs (21) in response to helper T-cell type 2 cytokines. Minor expression has been noted in other inflammatory cells including peripheral mononuclear cells and neutrophils (22). Its precise function is not fully known. However, PARC/CCL-18 has been demonstrated to preferentially attract naive T cells to areas of injury, amplifying the initial inflammatory response (23). It can also stimulate lung fibroblasts to produce collagen by up-regulating the extracellular signal–regulated kinase-1/2 pathway (24). Serum concentrations of PARC/CCL-18 are elevated in patients with pulmonary fibrosis, which in turn correlate with increased fibrotic activity in the lungs and with reduced overall survival of these patients (8).

There is a paucity of data evaluating the role of PARC/CCL-18 in COPD. In a cross-sectional study, Pinto-Plata and colleagues showed that serum PARC/CCL-18 levels correlated significantly with reduced FEV$_1$ percent predicted values, increased the risk of exacerbation, and increased BODE Index, indicating poor prognosis (9). In another study, Hurst and colleagues demonstrated that during exacerbations, plasma PARC/CCL-18 levels increased by 10% compared with those during clinical stability (10), suggesting that this cytokine may be up-regulated during disease flare-ups and may be used as a biomarker of exacerbations. However, it should also be noted that although PARC/CCL-18 expression occurs mostly in the lungs, other organs including the prostate, bone marrow, blood vessels, and the liver also express this protein. Interestingly, serum PARC/CCL-18 levels rise during ischemic myocardial events and these levels predict future risk of cardiovascular morbidity and mortality (5). This latter observation may explain...
why in the LHS we observed a significant relationship between serum PARC/CCL-18 concentrations and the risk of cardiovascular hospitalization and mortality. Additional work will be needed to validate this early finding.

Although the LHS and the ECLIPSE study were conducted in different populations, across different time periods and with a different set of goals and objectives, there was remarkable consistency and complementarity of PARC/CCL-18 findings between the two studies. In both studies, serum PARC/CCL-18 concentrations were significantly related to increasing age, male sex, BMI, and smoking status. Interestingly, in both studies, ex-smokers had higher serum expression than did current smokers. Moreover, in both studies, total smoking exposure (as measured by pack-years of smoking) was not significantly associated with serum PARC/CCL-18 concentrations, indicating the importance of current smoking (or nonsmoking) status in modulating this protein. These clinical data are consistent with those of Kollert and colleagues, who showed that smoking attenuates PARC/CCL-18 expression by alveolar macrophages (25).

However, there were some notable discrepancies between the findings in the LHS and those in ECLIPSE. First, in the LHS but not in ECLIPSE, serum PARC/CCL-18 levels were associated with FEV\textsubscript{1}\ percent predicted. One possible reason is that the LHS had almost twice the sample size of ECLIPSE, which may have provided sufficient statistical power to detect this relationship. Another possibility is that the LHS studied predominantly patients with mild to moderate COPD whereas, in ECLIPSE, there was nearly equal representation of patients in GOLD class II and III and also a large representation of patients from GOLD class IV. It may be that the relationship of PAR/CCL-18 is (inversely) linear in earlier disease severity but nonlinear in later stages. The discordance in the FEV\textsubscript{1} data also raises the possibility that the relationship between FEV\textsubscript{1} and serum PAR/CCL-18 levels observed in the LHS could have been spurious. Additional work in other cohorts will be needed to determine which of these hypotheses, if any, are valid. Third, in LHS, total mortality was not associated with serum PAR/CCL-18 concentrations, whereas in ECLIPSE, it was significantly related. Fewer than 7% of the LHS participants died during an average follow-up of 8 years (resulting in an annual mortality rate of less than 1%). Thus, we may have lacked sufficient statistical power to assess mortality in the LHS. In contrast, by sampling patients with greater disease severity, patients in ECLIPSE had a higher mortality rate than those in the LHS, with nearly 10% mortality over 3 years of follow-up (resulting in an annual mortality rate of approximately 3%), resulting in more robust statistical power for this end point.

There were some limitations to the present study. Because only one additional lung function measurement was obtained after blood collection in the LHS, we could not determine the relationship of serum PAR/CCL-18 levels to the rate of descent in FEV\textsubscript{1}. Second, there were insufficient numbers of cardiovascular hospitalizations in ECLIPSE to determine the relationship of this protein with cardiovascular events and in the LHS, we did not have information about significant prognostic variables such as the BODE Index. As such, the value of serum PAR/CCL-18 above and beyond the BODE Index and other composite scores in predicting health outcomes in COPD is uncertain. In ECLIPSE, there was only a loose relationship between BODE Index scores and PAR/CCL-18 levels. Third, blood samples for the LHS have been stored at \(-80^\circ\mathrm{C}\) for more than a decade. Although the blood samples have been well preserved and not subjected to repeat freeze-thaw cycles, the effect of long-term storage on most serum proteins is uncertain. Nevertheless, it was reassuring that the serum PAR/CCL-18 levels in the LHS subjects were similar to those in the ECLIPSE subjects. Fourth, in the LHS, we measured multiple proteins (27 in total) and we cannot discount the possibility that the positive associations of serum PAR/CCL-18 to clinical end points in this cohort may have been spurious, owing to multiple comparisons. However, replication of some (but not all) of the findings of the LHS in ECLIPSE was reassuring. Last, it should be noted that serum PAR/CCL-18 measurements have not been standardized and as such absolute levels may not be comparable across studies. Thus, the data are best interpreted in relative (rather than absolute) terms.

In summary, these large COPD cohorts demonstrate PARC/CCL-18 as a promising serum biomarker in COPD. It is up-regulated in COPD and independently associated with important health outcomes such as total mortality and cardiovascular morbidity and mortality. Additional work needs to be done to validate these findings in other cohorts and, most importantly, to determine whether or not this protein is in the causal pathway of disease pathogenesis.

Author Disclosure: D.D.S. was a consultant for Schering-Plough and was on the Board of Advisory Board for GlaxoSmithKline (GSK) and AstraZeneca (AZ). He received lecture fees from GSK and AZ. He received grant support from AZ, Wyeth Pharmaceuticals, Merck Frost, GSK, and the NIH. B.M. is employed by and owns stocks of GSK. His spouse is also employed by and owns stocks of GSK. A.M. received grant support from GSK. S.F.P.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. X.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.K.S. was a consultant for GSK and AZ. He received lecture fees from GSK, AZ, and Bayer. He received grant support from GSK and the NIH. J.E.C. was an expert witness for Carlson, Capers, Vandenbergh & Lindquist and received grant support from Covidien Surgical Staples and the NIH. N.A.A. was on the Board or Advisory Board for GSK and he received free or reduced labor fees from GSK. J.M. was a consultant for Novartis, Genentech, MPlex, Centocor, and the ALA. He was on the Advisory Board for AZ, BIPi, GSK, MedImmune, and Spiration. He received grant support from GSK, BIPi, Forest, the NIH, and the ALA. He has other financial interests with Emphysis, Internune, Telacris, Otsuka, and Mannkind. He received lecture fees from the Translational Medicine PCE/LA, SLU, NYU, and VCU. H.Z. was on the Board or Advisory Board for Boehringer-Ingelheim (BI), AZ, Dey Pharmaceuticals, Schering-Plough, and Novartis. He received lecture fees from BI, AZ, Dey Pharmaceuticals, and GSK. He received grant support from BI, AZ, Pfizer, GSK, and Dey. B.R.C. was a consultant for GSK, BI, AZ, and Almirall. He was on the Board or Advisory Board for GSK, BI, AZ, Aeris, and Roche. He received institutional grant support from GSK, BI, Forrest, Aeris, and Pfizer. L.E.S. is employed by GSK. N.L. is employed by and owns stocks of GSK. W.M. was a consultant for Pfizer Pharmaceuticals and was on the Board of Directors for GSK and Pfizer. He received lecture fees from GSK and AZ. He received grant support from GSK and Pfizer. R.T.-S. is employed by and employee of and owns stocks of GSK. D.A.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Principal investigators and centers participating in ECLIPSE (NCT00292552): Bulgaria: Yavor Ivanov, Plevier; Kosta Kostov, Sofia. Canada: Jean Bourbeau, Montreal; Mark FitzGerald, Vancouver; BC; Ingrid Edgren, North Vancouver, BC; Dan Schuller, Omaha, NE; Kieran Killian, Hamilton, ON; Robert Levy, Vancouver, BC; Francois Maltais, Montreal, PQ; Denis O’Donnell, Kingston, ON. Czech Republic: Jan Krepekla, Praha. Denmark: Jørn Vestbo, Hvidovre. The Netherlands: Emiel Wouters, Horn. New Zealand: Dean Quinn, Wellington. Norway: Per Bakke, Bergen. Slovenia: Mitja Kosnik, Goliñik. Spain: Alvar Agusti, Jaume Sauleuda, Palma de Mallorca. Ukraine: Yuri Feschenko, Kiev; Vladimir Gavriusyk, Kiev; Lyudmila Yashina, Kiev; Nadezhda Monogarova, Donetsk. United Kingdom: Peter Calverley, Liverpool; David Lomas, Cambridge; William Macnee, Edinburgh; David Singh, Manchester; Joana Wenzel, London; United States: Edward Bocan, San Antonio, TX; Sidney Braman, Providence, RI; Richard Casaburi, Torrance, CA; Bart Celli, Boston, MA; Glenn Giessel, Richmond, VA; Mark Gottfried, Phoenix, AZ; Gary Greenwald, Rancho Mirage, CA; Nicola Hanania, Houston, TX; Don Mahler, Belmont; Robert Marks, Denver, CO; Stephen Rennard, Omaha, NE; Carolyn Rochester, New Haven, CT; Paul Scanlon, Rochester, MN; Dan Schuller, Omaha, NE; Frank Scirica, Pittsburgh, PA; Amir Sharafkhan, Houston, TX; Thomas Slater, St. Charles, MO; Edwin Silverman, Boston, MA; Adam Wanner, Miami, FL; Robert Wise, Baltimore, MD; Richard ZuWallack, Hartford, CT. Steering Committee: Harvey Coxson (Canada), Lisa Edwards (GlaxoSmithKline, USA), Katharine Knobil (Co-chair, GlaxoSmithKline, UK), David Lomas (UK), William MacNe (UK), Edwin Silverman (USA), Ruth Tal-Singer (GlaxoSmithKline, USA), Jørn Vestbo (Co-chair, Denmark), Julie Yates (GlaxoSmithKline, USA). Scientific Committee: Alvar Agusti (Spain), Peter Calverley (UK), Bartolome Cella (USA), Courteney Crimey (GlaxoSmithKline, USA), Gerry Hagan (GlaxoSmithKline, UK), William MacNe (Chair, UK), Bruce Miller (GlaxoSmithKline, USA), Stephen Rennard (USA), Ruth Tal-Singer (GlaxoSmithKline, USA), Emiel Wouters (The Netherlands), Julie Yates (GlaxoSmithKline, USA).
References


